Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Price Target at $33.17

Shares of Immunome, Inc. (NASDAQ:IMNM) have earned an average rating of “Moderate Buy” from the fourteen analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $33.1667.

Several equities research analysts recently issued reports on IMNM shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Truist Financial raised their price objective on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Citigroup reiterated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Finally, Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $22.21 on Friday. Immunome has a fifty-two week low of $8.66 and a fifty-two week high of $27.65. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of -9.33 and a beta of 2.07. The firm’s 50-day simple moving average is $21.02 and its 200 day simple moving average is $21.96.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. On average, sell-side analysts predict that Immunome will post -2.06 EPS for the current year.

Insider Buying and Selling at Immunome

In other Immunome news, Director Isaac Barchas sold 101,050 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00. Following the completion of the sale, the director directly owned 308,504 shares of the company’s stock, valued at approximately $6,515,604.48. This represents a 24.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 1,092 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $25.00, for a total transaction of $27,300.00. Following the completion of the sale, the insider owned 1,092 shares of the company’s stock, valued at approximately $27,300. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 472,142 shares of company stock valued at $10,262,648 in the last quarter. 7.21% of the stock is owned by company insiders.

Institutional Trading of Immunome

A number of institutional investors and hedge funds have recently modified their holdings of IMNM. T. Rowe Price Investment Management Inc. boosted its position in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after purchasing an additional 5,003,824 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after purchasing an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA increased its position in shares of Immunome by 55.2% during the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. State Street Corp increased its position in shares of Immunome by 37.9% during the 4th quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after purchasing an additional 1,064,027 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Immunome by 8,659.2% during the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after purchasing an additional 2,823,144 shares during the period. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.